Physician profile
Mark W Ryan
NPI 1568020626
$1,897.03
in general payments reported to CMS, 2019-2025
28 companies · $627 in 2025
The $627 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $255 · 2023: $281 · 2024: $563 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $214.18 | 2021-2025 | |
| Pfizer INC. | $167.68 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.37 | 2021-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $144.92 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $112.77 | 2022-2024 | Spravato |
| Glaxosmithkline, LLC. | $94.83 | 2022-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $87.99 | 2024-2025 | Veozah |
| Indivior INC. | $80.58 | 2022-2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $79.81 | 2021 | |
| Lundbeck LLC | $73.67 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $70.58 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Merck Sharp & Dohme LLC | $68.52 | 2024-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Novo Nordisk INC | $64.30 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $58.12 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $56.04 | 2023-2025 | Otezla, Repatha, Evenity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $51.35 | 2022 | |
| Axsome Therapeutics, INC. | $39.03 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $36.64 | 2021 | |
| Aimmune Therapeutics, INC. | $34.23 | 2025 | Vowst |
| Corcept Therapeutics | $33.37 | 2024 | Korlym |
| Braeburn INC. | $29.51 | 2024 | Brixadi |
| Alkermes, INC. | $28.66 | 2025 | Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.99 | 2025 | Xifaxan |
| Impel Pharmaceuticals INC. | $21.93 | 2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $16.27 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2025 | Jardiance |
| Alfasigma USA, INC. | $14.44 | 2021 | |
| Sanofi Pasteur INC. | $13.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.